Titration doses of maridebart cafraglutide

TW202639157APending Publication Date: 2026-10-01AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114145592
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-06-17
Filing Date
2025-11-21
Publication Date
2026-10-01

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention relates to methods of treating obesity and obesity-related conditions while also reducing gastrointestinal side-effects associated with administration of GLP-1R agonists. Included are titrations of maridebart cafraglutide doses.
Need to check novelty before this filing date? Find Prior Art